Healthcare policy ahead of the US presidential election
Following the executive order on 13 September to lower drug prices in the United States, the battleground over US healthcare is taking shape and could fundamentally impact the outlook of the global pharmaceutical industry—all while the coronavirus disease 2019 (COVID-19) pandemic continues to dominate the political agenda.
Listen to the roundtable session with the IHS Markit life sciences team, where key discussion points will cover:
- The introduction of a "most favored nation" policy on drug pricing in the US—how real and how deep are the risks to the pharmaceutical sector?
- Healthcare policy ahead of the presidential election
- Impact of COVID-19 on hospitals and healthcare sector